Resources
10 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 2/18/2021 (updated 4/4/2024)
Opioid use disorder (OUD), a chronic disease, is a major public health problem. Despite availability of effective treatment, too few people receive it and treatment retention is low. Understanding barriers and facilitators of treatment access and retention is needed to improve outcomes for people with OUD.
In this study we sought to assess 3-month outcomes from a patient-centered practice that included MAT with buprenorphine or naltrexone plus the option to participate in psychosocial treatments. The psychosocial treatments included case management, psychotherapy, peer recovery groups such as Narcotics Anonymous or Smart Recovery, or peer support through a local harm reduction program.
Posted 10/12/2020 (updated 3/29/2024)
This report summarizes current (as of 2011) guidelines or recommendations published by multiple agencies of the U.S. Department of Health and Human Services (DHHS) for prevention and control of human immunodeficiency virus (HIV) infection, viral hepatitis, sexually transmitted diseases (STDs), and tuberculosis (TB) for persons who use drugs illicitly.
Posted 1/28/2020 (updated 3/28/2024)
The following guidelines introduce what has been learned from the sheriffs’ and jail administrators’ innovative use of MAT, describing the essential components of these programs and analyzing the latest research on how these programs are best implemented, as well as the medications approved for opioid use disorders.
Posted 11/21/2019 (updated 3/28/2024)
The New York State Department of Health (NYSDOH) convened a Technical Working Group on Resuscitation Training in Naloxone Programs to ensure that overdose programs in New York State (NYS) and elsewhere are afforded the best possible resuscitation protocol guidance tailored to suspected opioid overdoses in diverse settings.
Posted 11/21/2019 (updated 3/28/2024)
North Carolina Harm Reduction Naloxone Log Template
Posted 5/11/2020 (updated 3/28/2024)
This fact sheet describes changes to Oregon Health Authority (OHA) reimbursement for Medication-Assisted Treatment drugs administered to fee-for-service Oregon Health Plan members, effective January 1, 2019.
Posted 8/24/2020 (updated 3/28/2024)
Syringe service programs (SSPs), which provide access to sterile syringes and other injection equipment and their safe disposal after use,* represent a highly successful human immunodeficiency virus (HIV) prevention intervention. SSPs are associated with a 58% reduction in the incidence of HIV infection among persons who inject drugs. In addition, SSPs have led efforts to prevent opioid overdose deaths by integrating evidence-based opioid overdose education and naloxone distribution (OEND) programs. OEND programs train laypersons to respond during overdose events and provide access to naloxone and directions for drug delivery. SSPs are ideal places for OEND because they provide culturally relevant services designed to reach persons at high risk for experiencing or observing an opioid overdose.
Posted 8/18/2020 (updated 3/28/2024)
This guide was created for harm reduction medical staff and volunteers as a resource about the types of wounds common with injection drug use and also to increase knowledge about treatment modalities for this population. Skin and soft-tissue infections are the most common cause of hospitalization among people who inject drugs.
Posted 6/8/2023 (updated 3/27/2024)
There are multiple systems that can help individuals to address substance use disorder (SUD). A new report from the Addiction and Public Policy Initiative of the O’Neill Institute for National and Global Health Law at Georgetown Law Center discusses how these multiple systems are often disjointed which creates barriers for those needing to access services for SUD.
Posted 9/28/2023 (updated 3/27/2024)
The University of Vermont Center on Rural Addiction (UVM CORA), the University of Rochester, and the Fletcher Group have conducted an online survey assessing SUD stigma (including stigmatizing language), treatment needs and barriers, and concerns through the perspectives of rural, RCORP-affiliated practitioners. The data report explores the findings of the survey, including practitioner recommendations on improving access to OUD treatment.